Company intelligence / Profile preview

Nant Cancer Stem Cell

Culver City, California, United States

Ownership: Private
Employees: ~525
Development stage: Other

Overview

NANT Cancer Vaccine (NCV) programs have demonstrated durable remissions and improved safety profiles compared to standard chemotherapy in Phase 1/2 trials for multiple cancer types; trials are ongoing with expansion into more indications

Therapeutic areas: OncologyInfectious Diseases
Modalities: Cell therapyVaccineMonoclonal antibodySmall moleculeCytokineRecombinant proteinAdenoviral vector-based therapyYeast-based vaccineStem cell therapy
Industry: Biotech

Partnerships

NantHealth (integration of molecular profiling)National Marrow Donor Program (for stem cell trials)Sorgente (GPS Cancer diagnostic in Italy)

Beyond the preview

Go deeper on Nant Cancer Stem Cell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nant Cancer Stem Cell.

Explore the full profile